p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
作者： E M Berns , J G Klijn , W L van Putten , H H de Witte , M P Look
DOI: 10.1200/JCO.1998.16.1.121
关键词:
摘要: PURPOSEMutations of the p53 gene are frequently observed in primary breast cancer and accumulation protein has been used as a surrogate marker inactivation. Previous studies have shown that is related to poor prognosis cancer. We studied whether predictive factor for response tamoxifen treatment patients with recurrent cancer.PATIENTS AND METHODSLevels p53, estrogen receptor (ER), progesterone (PgR), urokinase-type plasminogen activator (uPA) were assayed cytosolic extracts derived from tumors 401 tamoxifen-naive who developed disease. All study received therapy upon relapse (median follow-up, 69 months). Association tested factors was by logistic regression analysis, survival after start Cox univariate multivariate analysis.RESULTSp53 levels (median,...
ru.nl
sci-hub.se 参考文章(35)
KATHRYN B. HORWITZ, LISA L. WEI, SCOT M. SEDLACEK, CAROLYN N. D'ARVILLE, Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Progress in Hormone Research. ,vol. 41, pp. 249- 316 ,(1985) , 10.1016/B978-0-12-571141-8.50010-X
Vincent F. Vellucci, Zhao-ling Zhou, Michael Reiss, Mutant p53 Tumor Suppressor Gene Causes Resistance to Transforming Growth Factor β1 in Murine Keratinocytes Cancer Research. ,vol. 53, pp. 899- 904 ,(1993)
M S Greenblatt, W P Bennett, M Hollstein, C C Harris, Mutations in the p53 Tumor Suppressor Gene: Clues to Cancer Etiology and Molecular Pathogenesis Cancer Research. ,vol. 54, pp. 4855- 4878 ,(1994)
M. Bontenbal, H. A. Peters, M. Schmitt, F. Jänicke, W. L. J. Van Putten, J. A. Foekens, J. G. M. Klijn, Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients Cancer Research. ,vol. 52, pp. 6101- 6105 ,(1992)
H Portengen, H A Peters, J Alexieva-Figusch, H L Krijnen, W L van Putten, J A Foekens, J G Klijn, Prognostic Value of Estrogen and Progesterone Receptors Measured by Enzyme Immunoassays in Human Breast Tumor Cytosols Cancer Research. ,vol. 49, pp. 5823- 5828 ,(1989)
Frederick C. Koerner, Ann D. Thor, Susan M. Edgerton, Marie-Christine Rio, Jean-Pierre Bellocq, Pierre Chambon, Laurent H. Schwartz, Joanna M. Sawicka, pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Research. ,vol. 51, pp. 624- 628 ,(1991)
R M Elledge, S Green, L Howes, G M Clark, M Berardo, D C Allred, R Pugh, D Ciocca, P Ravdin, J O'Sullivan, S Rivkin, S Martino, C K Osborne, bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Journal of Clinical Oncology. ,vol. 15, pp. 1916- 1922 ,(1997) , 10.1200/JCO.1997.15.5.1916
JA Foekens, H Portengen, MP Look, WLJ van Putten, B Thirion, M Bontenbal, JGM Klijn, Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. British Journal of Cancer. ,vol. 70, pp. 1217- 1223 ,(1994) , 10.1038/BJC.1994.476
Richard M. Elledge, D. Craig Allred, The p53 tumor suppressor gene in breast cancer. Breast Cancer Research and Treatment. ,vol. 32, pp. 39- 47 ,(1994) , 10.1007/BF00666204
GM Horne, JJ Anderson, DG Tiniakos, GG McIntosh, MD Thomas, B Angus, JA Henry, TWJ Lennard, CHW Horne, p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry British Journal of Cancer. ,vol. 73, pp. 29- 35 ,(1996) , 10.1038/BJC.1996.6